In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B-protein
factors	I-protein
activating	O
the	O
expression	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
GM-CSF	I-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
directs	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

The	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B-DNA
constructs	I-DNA
.	O

We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
binds	O
specifically	O
to	O
this	O
site	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B-DNA
site	I-DNA
located	O
upstream	O
of	O
the	O
PU.1	B-DNA
site	I-DNA
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
.	O

C/EBP	B-protein
alpha	I-protein
is	O
the	O
major	O
CCAAT/enhancer-binding	B-protein
protein	I-protein
(	O
C/EBP	B-protein
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU.1	B-DNA
site	I-DNA
or	O
the	O
C/EBP	B-DNA
site	I-DNA
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
activity	O
in	O
myelomonocytic	B-cell_type
cells	I-cell_type
only	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B-protein
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	B-protein
)	O
when	O
binding	O
the	O
GM-CSF	B-protein
receptor	I-protein
alpha	I-protein
promoter	O
PU.1	B-DNA
site	I-DNA
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B-protein
on	O
a	O
myeloid	B-DNA
PU.1	I-DNA
binding	I-DNA
site	I-DNA
.	O

The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	B-DNA
cell	I-DNA
enhancer	I-DNA
sites	I-DNA
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	B-protein
to	O
extracts	O
from	O
certain	O
nonmyeloid	B-cell_type
cell	I-cell_type
types	I-cell_type
which	O
do	O
not	O
express	O
PU.1	B-protein
,	O
including	O
T	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
from	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU-SF	B-protein
complex	I-protein
binds	O
to	O
PU.1	B-protein
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	B-DNA
promoters	I-DNA
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	B-DNA
site	I-DNA
adjacent	O
to	O
a	O
single-stranded	O
region	O
.	O

Expression	O
of	O
PU.1	B-protein
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
can	O
activate	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Deletion	O
of	O
the	O
amino-terminal	B-protein
region	I-protein
of	O
PU.1	B-protein
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU-SF	B-protein
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU-SF	B-protein
complex	I-protein
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
C/EBP	B-protein
alpha	I-protein
can	O
also	O
active	O
the	O
GM-CSF	B-DNA
receptor	I-DNA
alpha	I-DNA
promoter	I-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

HMG-I	B-protein
binds	O
to	O
GATA	B-DNA
motifs	I-DNA
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B-protein
protein	I-protein
HMG-I	B-protein
to	O
the	O
human	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
.	O

We	O
find	O
that	O
HMG-I	B-protein
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	B-DNA
motifs	I-DNA
in	O
the	O
gamma-globin	B-DNA
promoter	I-DNA
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	B-protein
factor	I-protein
GATA-1	I-protein
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T-C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	B-protein
results	O
in	O
overexpression	O
of	O
gamma-globin	B-protein
in	O
adult	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
HPFH	B-cell_type
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	B-DNA
promoter	I-DNA
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	B-protein
does	O
not	O
bind	O
to	O
this	O
mutant	B-DNA
sequence	I-DNA
.	O

A	O
survey	O
of	O
GATA	B-DNA
motifs	I-DNA
from	O
other	O
globin	B-DNA
cis-elements	I-DNA
demonstrates	O
HMG-I	B-protein
binding	O
to	O
most	O
of	O
them	O
.	O

These	O
findings	O
implicate	O
HMG-I	B-protein
in	O
the	O
HPFH	B-cell_type
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B-protein
complexes	I-protein
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	B-protein
tyrosine	I-protein
kinases	I-protein
in	O
human	B-protein
T	I-protein
cell	I-protein
leukemia	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HTLV-1	I-protein
)	I-protein
tax	I-protein
protein	I-protein
or	O
virus-transformed	B-cell_line
cells	I-cell_line
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	B-protein
encoded	I-protein
protein	I-protein
tax	B-protein
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	B-protein
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B-protein
transforms	O
mouse	B-cell_type
fibroblasts	I-cell_type
but	O
not	O
thymocytes	B-cell_type
,	O
despite	O
comparable	O
levels	O
of	O
tax	B-protein
expression	O
in	O
both	O
tissues	O
.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	B-protein
protein	I-protein
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	B-protein
transformed	B-cell_line
fibroblast	I-cell_line
B	I-cell_line
line	I-cell_line
and	O
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
lymphoid	I-cell_line
lines	I-cell_line
,	O
but	O
not	O
in	O
thymocytes	B-cell_type
from	O
Thy-tax	O
transgenic	O
mice	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B-protein
kinase	I-protein
specific	I-protein
antibodies	I-protein
,	O
identified	O
p130	O
as	O
Jak2	B-protein
in	O
the	O
tax	B-protein
transformed	O
mouse	B-cell_line
fibroblastic	I-cell_line
cell	I-cell_line
line	I-cell_line
and	O
Jak3	B-protein
in	O
HTLV-1	B-cell_line
transformed	I-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Phosphorylation	O
of	O
Jak2	B-protein
in	O
tax	B-cell_line
transformed	I-cell_line
cells	I-cell_line
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	B-cell_line
cells	I-cell_line
using	O
a	O
supernatant	O
from	O
the	O
B	B-cell_line
line	I-cell_line
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B-protein
neutralizing	I-protein
antibodies	I-protein
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	B-protein
kinases	I-protein
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	B-cell_type
infected	I-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Regulation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
by	O
hydroxyurea	O
in	O
human	B-cell_line
K562	I-cell_line
cells	I-cell_line
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O

Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B-protein
hemoglobin	I-protein
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	B-DNA
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

HU	O
induced	O
a	O
dose-dependent	O
stimulation	O
of	O
c-jun	B-DNA
synthesis	O
.	O

The	O
levels	O
of	O
c-jun	B-RNA
mRNA	I-RNA
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h	O
.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O

Both	O
nuclear	O
run-on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c-jun	B-RNA
mRNA	I-RNA
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c-jun	B-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
jun	B-protein
protein	I-protein
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	B-cell_line
treated	I-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	B-protein
/CAT	B-protein
activity	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	B-DNA
during	O
erythroid	O
differentiation	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
,	O
dose-response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B-protein
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	B-protein
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	B-protein
-induced	O
B-cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B-protein
receptor	I-protein
function	O
.	O

The	O
decrease	O
in	O
PWM	B-protein
-generated	O
B-cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid-mediated	O
induction	O
of	O
interleukin-1	B-protein
receptor	I-protein
synthesis	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

Application	O
of	O
a	O
``	O
formamide	O
free	O
''	O
and	O
thus	O
``	O
material	O
preserving	O
''	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	B-DNA
of	O
the	O
myf3	B-DNA
gene	I-DNA
revealed	O
the	O
following	O
results	O
:	O
Human	B-cell_type
rhabdomyosarcoma	I-cell_type
cells	I-cell_type
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	B-DNA
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O

RNase	B-protein
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Correspondingly	O
,	O
RNase	B-protein
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O

In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O

Oncogenicity	O
of	O
human	B-cell_line
papillomavirus-	I-cell_line
or	I-cell_line
adenovirus-transformed	I-cell_line
cells	I-cell_line
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
.	O

The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B-protein
and	O
E7	B-protein
proteins	I-protein
to	O
target	B-cell_type
cells	I-cell_type
for	O
rejection	O
by	O
the	O
host	B-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
response	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B-protein
-and	O
E7	B-protein
-expressing	O
human	B-cell_line
fibroblastic	I-cell_line
or	I-cell_line
keratinocyte-derived	I-cell_line
human	I-cell_line
cells	I-cell_line
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	B-cell_type
or	O
interferon	B-cell_line
(	I-cell_line
IFN	I-cell_line
)	I-cell_line
-activated	I-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

Cells	O
expressing	O
the	O
E1A	B-protein
oncoprotein	I-protein
were	O
selectively	O
killed	O
by	O
unstimulated	B-cell_line
NK	I-cell_line
cells	I-cell_line
,	O
while	O
the	O
same	O
parental	B-cell_type
cells	I-cell_type
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B-protein
oncoprotein	I-protein
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O

The	O
ability	O
of	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	B-protein
's	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i.e.	O
,	O
non-viral	B-cell_line
oncogene-expressing	I-cell_line
)	O
but	O
not	O
virally	B-cell_line
transformed	I-cell_line
cells	I-cell_line
.	O

E1A	B-protein
blocked	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

The	O
extent	O
of	O
IFN	B-protein
-induced	O
NK	O
cell	O
killing	O
of	O
E1A-expressing	B-cell_line
cells	I-cell_line
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B-protein
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B-protein
to	O
block	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
in	O
target	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
E7	B-protein
blocked	O
neither	O
IFN	B-protein
-stimulated	O
gene	O
expression	O
nor	O
IFN	B-protein
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV-transformed	B-cell_line
cells	I-cell_line
by	O
IFN-activated	B-cell_line
NK	I-cell_line
cells	I-cell_line
.	O

In	O
conclusion	O
,	O
E1A	B-protein
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	B-cell_type
cell	I-cell_type
response	O
,	O
whereas	O
the	O
E7	B-protein
oncoprotein	I-protein
lacks	O
this	O
activity	O
.	O

Regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B-protein
-induced	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
calcineurin	B-protein
is	O
also	O
sufficient	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC-dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
.	O

While	O
PKC	B-protein
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
co-activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
or	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
selective	O
PKC	B-protein
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA-induced	O
IkB	B-protein
alpha	I-protein
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B-protein
alpha	I-protein
induced	O
by	O
TNF-alpha	B-protein
,	O
a	O
PKC	B-protein
-independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B-protein
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	B-protein
not	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B-protein
calcineurin	B-protein
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	B-protein
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B-protein
alpha	I-protein
phosphorylation	O
and	O
degradation	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O

Oxidative	O
stress	O
enhances	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activity	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B-protein
cytokines	I-protein
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O

Alpha-tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF-kappa	B-protein
B	I-protein
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	O
and	O
an	O
increase	O
in	O
tumor	B-RNA
necrosis	I-RNA
factor-alpha	I-RNA
(	I-RNA
TNF-alpha	I-RNA
)	I-RNA
messenger	I-RNA
RNA	I-RNA
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha-tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	B-protein
B	I-protein
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	B-protein
cytokine	I-protein
synthesis	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
through	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
synthesis	O
[	O
see	O
comments	O
]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	B-protein
and	O
of	O
several	O
cell	B-protein
surface	I-protein
molecules	I-protein
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
in	O
mice	O
and	O
cultured	B-cell_line
cells	I-cell_line
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF-kappa	B-protein
B	I-protein
in	O
inactive	B-protein
cytoplasmic	I-protein
complexes	I-protein
.	O

Because	O
NF-kappa	B-protein
B	I-protein
activates	O
many	O
immunoregulatory	B-DNA
genes	I-DNA
in	O
response	O
to	O
pro-inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti-inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
by	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
.	O

T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B-protein
expression	O
by	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
(	O
VDR	B-protein
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	B-protein
expression	O
by	O
cotransfecting	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
IL-2	B-DNA
promoter/reporter	I-DNA
constructs	I-DNA
and	O
a	O
VDR	B-DNA
overexpression	I-DNA
vector	I-DNA
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B-DNA
region	I-DNA
encompassing	O
an	O
important	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
,	O
NF-AT-1	B-DNA
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
,	O
NFATp	B-protein
,	O
as	O
well	O
as	O
by	O
AP-1	B-protein
.	O

VDR	B-protein
DNA-binding	I-protein
mutants	I-protein
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B-protein
DNA-binding	I-protein
domain	I-protein
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B-protein
expression	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B-protein
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B-protein
repression	O
.	O

By	O
combining	O
partially	B-protein
purified	I-protein
proteins	I-protein
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	B-protein
complex	I-protein
upon	O
inclusion	O
of	O
VDR	B-protein
or	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
.	O

Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	B-protein
X	I-protein
receptor	I-protein
heterodimer	I-protein
blocks	O
NFATp/AP-1	B-protein
complex	I-protein
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	B-DNA
element	I-DNA
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B-protein
activators	I-protein
of	O
the	O
IL-2	B-DNA
gene	I-DNA
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

Tissue-specific	O
regulation	O
of	O
the	O
rabbit	B-DNA
15-lipoxygenase	I-DNA
gene	I-DNA
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
a	O
transcriptional	B-DNA
silencer	I-DNA
.	O

The	O
15-lipoxygenase	B-DNA
(	I-DNA
lox	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	B-cell_type
cells	I-cell_type
but	O
also	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
and	O
eosinophils	B-cell_type
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
of	O
the	O
15-lox	B-DNA
gene	I-DNA
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
in	O
two	O
erythroid	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	B-DNA
'silencer	I-DNA
'	I-DNA
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	B-DNA
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	B-protein
factor	I-protein
present	O
in	O
non-	O
erythroid	B-cell_type
cells	I-cell_type
but	O
not	O
in	O
erythroid	B-cell_type
cells	I-cell_type
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B-DNA
sites	I-DNA
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B-DNA
lox	I-DNA
promoter	I-DNA
fragment	I-DNA
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
DNA	I-DNA
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
GATA	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Phosphorylation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NFATp	B-protein
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	B-cell_line
A-treated	I-cell_line
human	I-cell_line
B	I-cell_line
and	O
T	B-cell_type
cells	I-cell_type
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	B-cell_type
cells	I-cell_type
(	O
NFAT	B-protein
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B-protein
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B-protein
component	O
to	O
the	O
nucleus	O
.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B-cell_line
B	I-cell_line
and	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B-protein
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B-protein
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B-protein
or	O
alkaline	B-protein
phosphatase	I-protein
restores	O
NFATp	B-protein
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B-protein
complex	I-protein
with	O
Fos	B-protein
and	O
Jun	B-protein
proteins	O
.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA-sensitive	O
regulation	O
of	O
NFATp	B-protein
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O

Transcription	B-protein
factors	I-protein
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time-frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL-2	B-DNA
gene	I-DNA
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	B-DNA
gene	I-DNA
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
and	O
Oct1	B-protein
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B-protein
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	B-RNA
mRNA	I-RNA
and	O
secretion	O
of	O
IL-2	B-protein
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B-protein
factor	I-protein
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
extracted	O
from	O
mitogen-stimulated	B-cell_type
cells	I-cell_type
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	O
and	O
NF-AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	B-protein
proteins	I-protein
,	O
such	O
as	O
transcription	B-protein
factors	I-protein
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Sex	O
and	O
age	O
distribution	O
of	O
1	B-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
normal	O
human	O
subjects	O
.	O

Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O

Twenty	O
two	O
healthy	O
men	O
aged	O
21-66	O
yr	O
(	O
mean	O
+/-	O
SD	O
41.0	O
+/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O
yr	O
(	O
38.9	O
+/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+/-	O
0.92	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
vs	O
4.43	O
+/-	O
1.38	O
fmol/10	O
(	O
7	O
)	O
PBMC	B-cell_type
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O

No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O
women	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B-protein
receptors	I-protein
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O

Expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Helix-loop-helix	B-protein
(	I-protein
HLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
are	O
involved	O
in	O
cellular	O
growth	O
and	O
differentiation	O
.	O

The	O
Id	B-protein
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	B-protein
proteins	I-protein
,	O
in	O
a	O
dominantly	O
negative	O
fashion	O
,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B-protein
HLH	I-protein
proteins	I-protein
.	O

We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B-RNA
and	I-RNA
Id3	I-RNA
mRNA	I-RNA
in	O
human	B-cell_line
leukemia/lymphoma	I-cell_line
lines	I-cell_line
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	B-cell_line
normal	I-cell_line
human	I-cell_line
lymphocytes	I-cell_line
from	O
peripheral	O
blood	O
(	O
PBL	B-cell_type
)	O
.	O

The	O
Id2	B-RNA
mRNA	I-RNA
was	O
abundantly	O
expressed	O
in	O
5/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
and	O
Id3	B-RNA
mRNA	I-RNA
was	O
detected	O
in	O
4/12	B-cell_line
T-cell	I-cell_line
and	O
3/4	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
.	O

Interestingly	O
,	O
Id2	B-RNA
,	O
but	O
not	O
Id3	B-RNA
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4/5	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
infected	O
with	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
(	O
ATL-1k	B-cell_line
,	O
MT-2	B-cell_line
,	O
S-LB1	B-cell_line
)	O
and	O
type	O
II	O
(	O
Mo	B-cell_line
)	O
.	O

Another	O
unexpected	O
finding	O
was	O
that	O
T-cell	O
leukemias	O
and	O
T-cell	B-cell_line
lines	I-cell_line
often	O
expressed	O
either	O
Id2	B-RNA
or	O
Id3	B-RNA
mRNA	I-RNA
.	O

In	O
addition	O
,	O
resting	B-cell_type
PBL	I-cell_type
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
,	O
but	O
not	O
Id3	B-RNA
mRNA	I-RNA
.	O

Upon	O
PHA	B-protein
-stimulation	O
,	O
Id2	B-protein
expression	O
decreased	O
and	O
Id3	B-protein
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O
require	O
further	O
analysis	O
:	O
(	O
1	O
)	O
expression	O
of	O
Id2	B-RNA
mRNA	I-RNA
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV-I	O
or	O
-II	O
;	O
(	O
2	O
)	O
T-cells	O
usually	O
express	O
either	O
Id2	B-protein
or	O
Id3	B-RNA
mRNA	I-RNA
,	O
but	O
B-cells	O
often	O
express	O
both	O
simultaneously	O
;	O
(	O
3	O
)	O
non-dividing	O
,	O
normal	O
PBL	B-cell_type
express	O
high	O
levels	O
of	O
Id2	B-protein
and	O
no	O
Id3	B-RNA
mRNA	I-RNA
;	O
and	O
with	O
the	O
onset	O
of	O
cellular	O
proliferation	O
,	O
levels	O
of	O
Id2	B-RNA
mRNA	I-RNA
decrease	O
while	O
levels	O
of	O
Id3	B-RNA
mRNA	I-RNA
increase	O
,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	B-DNA
is	O
disparate	O
.	O

Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
.	O

Binding	O
of	O
plasma	B-protein
Factor	I-protein
VII/VIIa	I-protein
to	O
the	O
tissue	B-protein
factor	I-protein
(	I-protein
TF	I-protein
)	I-protein
receptor	I-protein
initiates	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

TF	O
expression	O
by	O
circulating	B-cell_type
monocytes	I-cell_type
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
in	O
monocytic	B-cell_type
cells	I-cell_type
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-DNA
gene	I-DNA
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	B-protein
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Critical	O
role	O
for	O
IL-6	B-protein
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B-protein
with	O
TCR	B-protein
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
STAT	I-protein
)	I-protein
proteins	I-protein
in	O
a	O
primary	O
TCR	B-protein
-mediated	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
have	O
been	O
explored	O
.	O

In	O
purified	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
nuclear	B-protein
STAT	I-protein
proteins	I-protein
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	B-protein
Abs	I-protein
.	O

These	O
STAT	B-protein
proteins	I-protein
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	B-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B-protein
Abs	I-protein
indicated	O
that	O
they	O
contained	O
STAT-3	B-protein
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B-protein
family	I-protein
.	O

The	O
induction	O
of	O
STAT	B-protein
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B-protein
factor	I-protein
produced	O
by	O
the	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

As	O
neutralizing	B-protein
anti-IL-6	I-protein
Abs	I-protein
effectively	O
down-regulated	O
the	O
early	O
induction	O
of	O
STAT	B-protein
proteins	I-protein
and	O
as	O
exogenously	O
added	O
IL-6	B-protein
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	B-protein
-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL-6	B-protein
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	B-protein
proteins	I-protein
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
.	O

B	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	B-DNA
cycle-associated	I-DNA
genes	I-DNA
in	O
quiescent	B-cell_type
and	I-cell_type
stimulated	I-cell_type
cells	I-cell_type
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	B-DNA
genes	I-DNA
,	O
cdc-2	B-DNA
,	O
cyclin	B-DNA
E	I-DNA
,	O
CD23	B-DNA
,	O
and	O
cyclin	B-DNA
D2	I-DNA
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV-mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	B-protein
,	O
anti-IgM	B-protein
,	O
and	O
IL4	B-protein
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	B-cell_type
cell	O
cycle	O
activation	O
.	O

Expression	O
of	O
the	O
chemokine	B-protein
receptor	I-protein
BLR2/EBI1	B-protein
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	B-protein
receptors	I-protein
that	O
are	O
related	O
to	O
Burkitt	B-protein
's	I-protein
lymphoma	I-protein
receptor	I-protein
1	I-protein
(	O
BLR1	B-protein
)	O
and	O
are	O
expressed	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B-protein
transmembrane	I-protein
receptor	I-protein
termed	O
BLR2	B-protein
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B-protein
coupled	I-protein
chemokine	I-protein
receptors	I-protein
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B-protein
EBI1	I-protein
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B-RNA
mRNA	I-RNA
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B-cell_line
and	I-cell_line
anti-CD3-treated	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
.	O

BLR2-specific	B-RNA
mRNA	I-RNA
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B-cell_line
virus	I-cell_line
positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B-DNA
gene	I-DNA
could	O
be	O
specifically	O
induced	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
negative	I-cell_line
BL	I-cell_line
41	I-cell_line
cells	I-cell_line
via	O
estrogen-mediated	O
activation	O
of	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
,	O
a	O
key	O
regulator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
in	O
immortalized	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B-protein
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
and	O
in	O
viral	O
pathogenesis	O
.	O

A	O
central	O
role	O
for	O
a	O
single	B-DNA
c-Myb	I-DNA
binding	I-DNA
site	I-DNA
in	O
a	O
thymic	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
.	O

Locus	B-DNA
control	I-DNA
regions	I-DNA
(	O
LCRs	B-DNA
)	O
are	O
powerful	O
assemblies	O
of	O
cis	B-DNA
elements	I-DNA
that	O
organize	O
the	O
actions	O
of	O
cell-type-specific	B-protein
trans-acting	I-protein
factors	I-protein
.	O

A	O
2.3-kb	B-protein
LCR	I-protein
in	O
the	O
human	B-DNA
adenosine	I-DNA
deaminase	I-DNA
(	I-DNA
ADA	I-DNA
)	I-DNA
gene	I-DNA
first	I-DNA
intron	I-DNA
,	O
which	O
controls	O
expression	O
in	O
thymocytes	B-cell_type
,	O
is	O
composed	O
of	O
a	O
200-bp	B-DNA
enhancer	I-DNA
domain	I-DNA
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	B-DNA
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	B-DNA
contains	O
a	O
28-bp	B-DNA
core	I-DNA
region	I-DNA
and	O
local	O
adjacent	O
augmentative	O
cis	B-DNA
elements	I-DNA
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c-Myb	B-DNA
binding	I-DNA
site	I-DNA
.	O

In	O
both	O
transiently	B-cell_line
cotransfected	I-cell_line
human	I-cell_line
cells	I-cell_line
and	O
stable	O
chromatin-integrated	B-cell_line
yeast	I-cell_line
cells	I-cell_line
,	O
c-Myb	B-protein
strongly	O
transactivated	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
contained	O
polymerized	B-DNA
core	I-DNA
sequences	I-DNA
.	O

c-Myb	B-protein
protein	I-protein
was	O
strongly	O
evident	O
in	O
T	B-cell_type
lymphoblasts	I-cell_type
in	O
which	O
the	O
enhancer	B-DNA
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	B-DNA
expression	O
with	O
that	O
of	O
mouse	B-DNA
ADA	I-DNA
and	O
human	B-DNA
ADA	I-DNA
LCR	I-DNA
-directed	O
transgene	O
expression	O
.	O

Point	O
mutation	O
of	O
the	O
c-Myb	B-DNA
site	I-DNA
within	O
the	O
intact	O
2.3-kb	B-protein
LCR	I-protein
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	B-DNA
activity	O
in	O
transgenic	B-cell_line
thymocytes	I-cell_line
.	O

Within	O
the	O
context	O
of	O
a	O
complex	B-DNA
enhancer	I-DNA
and	O
LCR	B-DNA
,	O
c-Myb	B-protein
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte-specific	B-DNA
gene	I-DNA
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O

A	O
regulatory	B-DNA
element	I-DNA
in	O
the	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
zinc	B-protein
finger	I-protein
proteins	I-protein
Sp1	B-protein
and	O
EGR-1	B-protein
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	B-protein
factors	I-protein
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
stimulated	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	B-DNA
element	I-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
(	I-DNA
NFAT	I-DNA
)	I-DNA
domain	I-DNA
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	B-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
region	I-DNA
(	O
ZIP	B-DNA
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B-protein
finger	I-protein
proteins	I-protein
:	O
the	O
constitutively	B-protein
expressed	I-protein
transcription	I-protein
factor	I-protein
Sp1	B-protein
and	O
the	O
inducible	B-protein
early	I-protein
growth	I-protein
response	I-protein
protein	I-protein
EGR-1	B-protein
.	O

In	O
unstimulated	B-cell_type
cells	I-cell_type
which	O
do	O
not	O
secrete	O
IL-2	B-protein
,	O
only	O
Sp1	B-protein
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B-cell_line
IL-2	I-cell_line
secreting	I-cell_line
cells	I-cell_line
the	O
inducible	B-protein
EGR-1	I-protein
protein	I-protein
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
the	O
ZIP	B-DNA
site	I-DNA
serves	O
as	O
an	O
activator	O
for	O
IL-2	B-protein
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	B-DNA
and	O
NFAT	B-DNA
binding	I-DNA
sites	I-DNA
is	O
required	O
for	O
maximal	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	B-DNA
site	I-DNA
for	O
IL-2	B-DNA
promoter	I-DNA
activity	O
.	O

Activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
by	O
the	O
LEF-1	B-protein
HMG	I-protein
protein	I-protein
on	O
nucleosome-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O

Lymphoid	B-protein
enhancer-binding	I-protein
factor	I-protein
1	I-protein
(	O
LEF-1	B-protein
)	O
is	O
a	O
regulatory	B-protein
high	I-protein
mobility	I-protein
group	I-protein
(	I-protein
HMG	I-protein
)	I-protein
protein	I-protein
that	O
activates	O
the	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
TCR	I-DNA
alpha	I-DNA
)	I-DNA
enhancer	I-DNA
in	O
a	O
context-restricted	O
manner	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus-1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
enhancer	I-DNA
,	O
which	O
contains	O
DNA-binding	B-DNA
sites	I-DNA
for	O
LEF-1	B-protein
and	O
Ets-1	O
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	B-protein
.	O

First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	B-DNA
site	I-DNA
inhibit	O
the	O
activity	O
of	O
multimerized	B-DNA
copies	I-DNA
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
and	O
that	O
LEF-1/GAL4	B-protein
can	O
activate	O
a	O
GAL4-substituted	B-DNA
HIV-1	I-DNA
enhancer	I-DNA
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O

Second	O
,	O
recombinant	B-protein
LEF-1	I-protein
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin-assembled	B-DNA
DNA	I-DNA
in	O
vitro	O
.	O

By	O
using	O
a	O
nucleosome	B-protein
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	B-DNA
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B-protein
(	O
or	O
LEF-1	B-protein
and	O
Ets-1	B-protein
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B-protein
protein	I-protein
,	O
Sp1	B-protein
.	O

Addition	O
of	O
TFE-3	B-protein
,	O
which	O
binds	O
to	O
an	O
E-box	B-DNA
motif	I-DNA
upstream	O
of	O
the	O
LEF-1	B-DNA
and	I-DNA
Ets-1	I-DNA
sites	I-DNA
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O

Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer-binding	B-protein
proteins	I-protein
(	O
LEF-1	B-protein
,	O
Ets-1	B-protein
,	O
and	O
TFE-3	B-protein
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B-protein
.	O

A	O
truncation	B-protein
mutant	I-protein
of	O
LEF-1	B-protein
(	O
HMG-88	B-protein
)	O
,	O
which	O
contains	O
the	O
HMG	B-protein
box	I-protein
but	O
lacks	O
the	O
trans-activation	B-protein
domain	I-protein
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B-DNA
DNA	I-DNA
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B-protein
domain	I-protein
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	B-protein
in	O
vitro	O
is	O
a	O
chromatin	B-DNA
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans-activation	B-protein
domain	I-protein
in	O
addition	O
to	O
the	O
HMG	B-protein
domain	I-protein
.	O

HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
induce	O
activation	O
of	O
activated	O
protein-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Activation	O
of	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-cell_line
positive	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV	O
,	O
gp	B-protein
160	I-protein
,	O
can	O
induce	O
activation	O
of	O
transcription	B-protein
factor	I-protein
,	I-protein
activated	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	B-protein
are	O
mediated	O
through	O
the	O
CD4	B-protein
molecule	I-protein
,	O
since	O
treatment	O
of	O
gp160	B-protein
with	O
soluble	O
CD4-IgG	B-protein
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B-protein
.	O

Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

The	O
gp160-induced	B-protein
AP-1	I-protein
complex	I-protein
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis-independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	B-protein
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	B-cell_type
cells	I-cell_type
:	O
pre-treatment	O
of	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
gp160	B-protein
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti-CD3	B-protein
-induced	O
interleukin-2	B-protein
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	B-protein
were	O
seen	O
with	O
anti-CD4	B-protein
mAb	I-protein
.	O

The	O
aberrant	O
activation	O
of	O
AP-1	B-protein
by	O
gp160	B-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	B-protein
containing	O
AP-1	B-DNA
sites	I-DNA
,	O
e.g	O
.	O
interleukin-3	B-protein
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
,	O
and	O
concurrently	O
lead	O
to	O
T	B-cell_type
cell	I-cell_type
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B-protein
secretion	O
.	O

